Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Palliative Care
Published in: BMC Palliative Care 1/2018

Open Access 01-12-2018 | Research article

Development of the Japanese version of an information aid to provide accurate information on prognosis to patients with advanced non–small-cell lung cancer receiving chemotherapy: a pilot study

Authors: Kikuo Nakano, Yoshihiro Kitahara, Mineyo Mito, Misato Seno, Shoji Sunada

Published in: BMC Palliative Care | Issue 1/2018

Login to get access

Abstract

Background

Without explicit prognostic information, patients may overestimate their life expectancy and make poor choices at the end of life. We sought to design the Japanese version of an information aid (IA) to provide accurate information on prognosis to patients with advanced non–small-cell lung cancer (NSCLC) and to assess the effects of the IA on hope, psychosocial status, and perception of curability.

Methods

We developed the Japanese version of an IA, which provided information on survival and cure rates as well as numerical survival estimates for patients with metastatic NSCLC receiving first-line chemotherapy. We then assessed the pre- and post-intervention effects of the IA on hope, anxiety, and perception of curability and treatment benefits.

Results

A total of 20 (95%) of 21 patients (65% male; median age, 72 years) completed the IA pilot test. Based on the results, scores on the Distress and Impact Thermometer screening tool for adjustment disorders and major depression tended to decrease (from 4.5 to 2.5; P = 0.204), whereas no significant changes were seen in scores for anxiety on the Japanese version of the Support Team Assessment Schedule or in scores on the Hearth Hope Index (from 41.9 to 41.5; p = 0.204). The majority of the patients (16/20, 80%) had high expectations regarding the curative effects of chemotherapy.

Conclusion

The Japanese version of the IA appeared to help patients with NSCLC maintain hope, and did not increase their anxiety when they were given explicit prognostic information; however, the IA did not appear to help such patients understand the goal of chemotherapy. Further research is needed to test the findings in a larger sample and measure the outcomes of explicit prognostic information on hope, psychological status, and perception of curability.
Appendix
Available only for authorised users
Literature
1.
2.
Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest. 2005;128(4):2933–43.CrossRefPubMed
3.
Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–9.CrossRefPubMed
4.
Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010;126(3):651–5.CrossRefPubMed
5.
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non–small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–25.CrossRefPubMedCentral
6.
Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–6.CrossRefPubMed
7.
Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA. 1998;279(21):1709–14.CrossRefPubMed
8.
Hancock K, Clayton JM, Parker SM, Wal d S, Butow PN, Carrick S, Currow D, Ghersi D, Glare P, Hagerty R, et al. Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review. Palliat Med. 2007;21(6):507–17.CrossRefPubMed
9.
Surbone A, Ritossa C, Spagnolo AG. Evolution of truth-telling attitudes and practices in Italy. Crit Rev Oncol Hematol. 2004;52(3):165–72.CrossRefPubMed
10.
Slingsby BT. Decision-making models in Japanese psychiatry: transitions from passive to active patterns. Soc Sci Med. 2004;59(1):83–91.CrossRefPubMed
11.
Mack JW, Cronin A, Taback N, Huskamp HA, Keating NL, Malin JL, Earle CC, Weeks JC. End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med. 2012;156(3):204–10.CrossRefPubMedPubMedCentral
12.
Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med. 2002;16(4):297–303.CrossRefPubMed
13.
Daneault S, Dion D, Sicotte C, Yelle L, Mongeau S, Lussier V, Coulombe M, Paillé P. Hope and noncurative chemotherapies: which affects the other? J Clin Oncol. 2010;28(13):2310–3.CrossRefPubMed
14.
Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MH. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol. 2004;22(9):1721–30.CrossRefPubMed
15.
Clayton JM, Butow PN, Arnold RM, Tattersall MH. Discussing life expectancy with terminally ill cancer patients and their carers: a qualitative study. Support Care Cancer. 2005;13(9):733–42.CrossRefPubMed
16.
17.
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007;18(2):317–23.CrossRefPubMed
18.
Kiely BE, Alam M, Blinman P, Tattersall MH, Stockler MR. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. Lung Cancer. 2012;77(3):537–44.CrossRefPubMed
19.
Herth K. Abbreviated instrument to measure hope: development and psychometric evaluation. J Adv Nurs. 1992;17(10):1251–9.CrossRefPubMed
20.
Akizuki N, Yamawaki S, Akechi T, Nakano T, Uchitomi Y. Development of an impact thermometer for use incombination with the distress thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manag. 2005;29(1):91–9.CrossRef
21.
Miyashita M, Yasuda M, Baba R, Iwase S, Teramoto R, Nakagawa K, Kizawa Y, Shima Y. Inter-rater reliability of proxy simple symptom assessment scale between physician and nurse: a hospital-based palliative care team setting. Eur J Cancer Care. 2010;19(1):124–30.CrossRef
22.
Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–25.CrossRefPubMedPubMedCentral
23.
Smith TJ, Dow LA, Virago EA, Khatcheressian J, Matsuyama R, Lyckholm LJ. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol. 2011;9(2):79–86.CrossRefPubMedPubMedCentral
24.
Sjoquist KM, Friedlander ML, O'Connell RL, Voysey M, King MT, Stockler MR, Oza AM, Gillies K, Martyn JK, Butow PN. Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study. Oncologist. 2013;18(11):1221–8.CrossRefPubMedPubMedCentral
25.
Barnett MM. Does it hurt to know the worst? -psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psychooncology. 2006;15(1):44–55.CrossRefPubMed
26.
Campbell TC, Carey EC, Jackson VA, Saraiya B, Yang HB, Back AL, Arnold RM. Discussing prognosis: balancing hope and realism. Cancer J. 2010;16(5):461–6.CrossRefPubMed
27.
Rodin G, Zimmermann C, Mayer C, Howell D, Katz M, Sussman J, Mackay JA, Brouwers M. Clinician-patient communication: evidence-based recommendations to guide practice in cancer. Curr Oncol. 2009;16(6):42–9.CrossRefPubMedPubMedCentral
28.
Blackhall LJ, Murphy ST, Frank G, Michel V, Azen S. Ethnicity and attitudes toward patient autonomy. JAMA. 1995;274(10):820–5.CrossRefPubMed
29.
Buiting HM, Rurup ML, Wijsbek H, van Zuylen L, den Hartogh G. Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study. BMJ. 2011;342:d1933.PubMedPubMedCentral
30.
Kaplowitz SA, Campo S, Chiu WT. Cancer patients’ desires for communication of prognosis information. Health Commun. 2002;14(2):221–41.CrossRefPubMed
31.
Kiely BE, McCaughan G, Christodoulou S, Beale PJ, Grimison P, Trotman J, Tattersall MH, Stockler MR. Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Support Care Cancer. 2013;21(2):369–76.CrossRefPubMed
32.
Pardon K, Deschepper R, Vander Stichele R, Bernheim JL, Mortier F, Bossuyt N, Schallier D, Germonpré P, Galdermans D, Van Kerckhoven W, et al. Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients. Support Care Cancer. 2012;20(10):2473–82.CrossRefPubMed
33.
Leighl NB, Shepherd FA, Zawisza D, Burkes RL, Feld R, Waldron J, Sun A, Payne D, Bezjak A, Tattersall MH. Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer. Br J Cancer. 2008;98(11):1769–73.CrossRefPubMedPubMedCentral
34.
Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29(17):2319–26.CrossRefPubMed
35.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.CrossRefPubMed
36.
Yoong J, Park ER, Greer JA, Jackson VA, Gallagher ER, Pirl WF, Back AL, Temel JS. Early palliative care in advanced lung cancer: a qualitative study. JAMA Intern Med. 2013;173(4):283–90.CrossRefPubMed
37.
van Vliet LM, van der Wall E, Plum NM, Bensing JM. Explicit prognostic information and reassurance about nonabandonment when entering palliative breast cancer care: findings from a scripted video-vignette study. J Clin Oncol. 2013;31(26):3242–9.CrossRefPubMed
38.
Sullivan DR, Forsberg CW, Ganzini L, Au DH, Gould MK, Provenzale D, Slatore CG. Longitudinal changes in depression symptoms and survival among patients with lung cancer: a national cohort assessment. J Clin Oncol. 2016;34(33):3984–91.CrossRefPubMedPubMedCentral
39.
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33.CrossRefPubMed
Metadata
Title
Development of the Japanese version of an information aid to provide accurate information on prognosis to patients with advanced non–small-cell lung cancer receiving chemotherapy: a pilot study
Authors
Kikuo Nakano
Yoshihiro Kitahara
Mineyo Mito
Misato Seno
Shoji Sunada
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Palliative Care / Issue 1/2018
Electronic ISSN: 1472-684X
DOI
https://doi.org/10.1186/s12904-018-0292-6

Other articles of this Issue 1/2018

BMC Palliative Care 1/2018 Go to the issue

Research article

Impact of the Macmillan specialist Care at Home service: a mixed methods evaluation across six sites

Research article

A review of paper-based advance care planning aids

Research article

Palliative care for people with schizophrenia: a qualitative study of an under-serviced group in need

Research article

Use of hospital palliative care according to the place of death and disease one year before death in 2013: a French national observational study

Research article

Benchmarking time to initiation of end-of-life homecare nursing: a population-based cancer cohort study in regions across Canada

Research article

Social workers’ involvement in advance care planning: a systematic narrative review